Arbutus Biopharma (ABUS) Accumulated Expenses (2013 - 2019)

Arbutus Biopharma has disclosed Accumulated Expenses across 5 years of filings, most recently posting $137000.0 for Q4 2019.

• Accumulated Expenses for Q4 2019 came in at $137000.0, down 89.71% year-over-year; the trailing twelve-month figure through Dec 2019 was $137000.0 (down 89.71% YoY), and the FY2019 annual result was $137000.0, down 89.71% from the prior year.
• Accumulated Expenses came in at $137000.0 for Q4 2019 at Arbutus Biopharma, down from $203000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.9 million in Q2 2015 to a low of $26000.0 in Q3 2015.
• The 3-year median for Accumulated Expenses is $272500.0 (2019), against an average of $620375.0.
• Peak annual rise in Accumulated Expenses reached 21.6% in 2015, while the deepest fall reached 98.26% in 2015.
• Arbutus Biopharma's Accumulated Expenses stood at $26000.0 in 2015, then jumped by 5019.23% to $1.3 million in 2018, then tumbled by 89.71% to $137000.0 in 2019.
• The last three Accumulated Expenses figures came in at $137000.0 (Q4 2019), $203000.0 (Q3 2019), and $342000.0 (Q2 2019), per Business Quant data.